2018 American Transplant Congress
Engineering Regulatory T Cells with Interleukin (IL-)2 Nanogel for Improved Alloimmune Suppression
Clinical trials of adoptively transferred regulatory T cells (TRegs) have been hindered by the short lifespan of these transferred TRegs. Systemic injection of low-dose interleukin…2018 American Transplant Congress
TLR2 with TCR Signaling Mobilizes Treg Lymphatic Migration
Background: Regulatory T cells (Treg) express high levels of lymphotoxin (LT) and bind the LT receptor (LTβR) on lymphatic endothelial cells (LEC). This receptor-ligand interaction…2017 American Transplant Congress
Utility of IL-2 Complexes in Promoting Vascularized Composite Allograft Survival.
Vascularized composite allografts (VCA) are a novel, life-enhancing form of transplantation (Tx). The complexity of host immune responses to VCA tissues, especially those involving skin,…2017 American Transplant Congress
Using Basiliximab Does Not Increase De Novo DSA Incidence but Reduces Cytomegalovirus Infections and Neoplastic Complications in Non-Sensitized Kidney Transplant Patients.
Background. In kidney transplantation, de novo donor specific antibodies (dnDSA) are associated with antibody-mediated rejection (AMR) and graft failure. After dnDSA development, 24% of the…2017 American Transplant Congress
The Effect of Low-Dose IL-2 in Clinical Facial Transplantation: Molecular and Immunological Response.
1Brigham and Women's Hospital, Boston; 2Beth Israel Deaconess Medical Center, Boston
BackgroundRegulatory T cells (Tregs) play a critical role in immune tolerance and low-dose recombinant IL-2 administration has been reported to expand Tregs in vivo. Although…2016 American Transplant Congress
IL-2 Therapy Restores the Impaired Function of Regulatory T Cells Induced by Calcineurin Inhibitors in Liver Transplantation.
Liver Science Department, King's College London, London, United Kingdom.
CD4+CD25+FOXP3+ regulatory T cells (Tregs) have an essential role in immune regulation and constitute a key target for cellular immunotherapies in transplantation. IL-2 is critical…2016 American Transplant Congress
Clinical Factors That Determine the More Appropriate Induction Agent: ATG versus IL-2 Receptor Antagonists.
Antithymocyte globulin (ATG) is recommended over IL-2 receptor antagonist (IL2) in high-risk recipients for induction immunosuppression. However, “high-risk” status has not been defined in an…2016 American Transplant Congress
In Vitro Reactivity of CD4+ T Cells Subsets from Hosts with Antigen Specific Transplant Tolerance Mediated by CD4+CD25+T Cells.
Immune Tolerance Laboratory, UNSW Australia, Sydney, NSW, Australia.
In animals with transplant tolerance without lympho-hemopoietic chimerism peripheral T cells reactive to donor are not deleted, but their capacity to effect rejection is inhibited…2015 American Transplant Congress
Propensity Score-Weighted Analysis of Induction Therapies in Live Donor Kidney Transplantation in Modern Immunosuppression Era
1Medicine, UTSW, Dallas, TX; 2Clinical Sciences, UTSW, Dallas, TX; 3Surgery, UTSW, Dallas, TX.
Background: Induction therapy with interleukin-2 receptor antagonist (IL2-RA) is recommended as a first line agent in living donor renal transplantation (LRT). However, use of IL2-RA…2015 American Transplant Congress
Induction With an Interleukin-2 Receptor Antagonist in Sensitized Adult Kidney Transplant Recipients Is Highly Effective and Safe
Background: The effectiveness and safety of induction with basiliximab (IL2RA) in sensitized kidney transplant recipients is not clearly established. The aim of this study was…
American Transplant Congress abstracts